Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $1.00B
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.83M
Average 1.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$18.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
CRISPR Therapeutics AG NASDAQ:CRSP | $4.10B | $42.24 | Not rated | -9.2 | -23.26% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +15.53% |
Sana Biotechnology, Inc. NASDAQ:SANA | $605.26M | $2.02 | Not rated | -3.5 | -48.82% |
Editas Medicine, Inc. NASDAQ:EDIT | $334.92M | $2.17 | Not rated | -2.4 | -32.14% |
Autolus Therapeutics plc NASDAQ:AUTL | $311.41M | $1.17 | Not rated | -1.4 | -22.87% |
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | $1.65 | Not rated | -1.8 | +155.37% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -26.74% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | $1.28 | Not rated | -1.8 | -3.81% |
Nkarta, Inc. NASDAQ:NKTX | $85.23M | $1.19 | Not rated | -2.0 | -37.43% |
Continue the stock analysis
Jump to another research area for this company.